Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Regeneron Pharmaceuticals fell $5.93 (-2.2%) to $262.71 on light volume. Throughout the day, 723,955 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,239,100 shares. The stock ranged in price between $258.32-$270.82 after having opened the day at $267.23 as compared to the previous trading day's close of $268.64. Other companies within the Drugs industry that declined today were:
(
), down 37.2%,
(
), down 12.0%,
(
), down 10.1% and
(
), down 9.1%.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $25.5 billion and is part of the health care sector. Shares are up 55.5% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.
TheStreet Ratings rates
Regeneron Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Regeneron Pharmaceuticals Ratings Report.
On the positive front,
(
), up 15.9%,
(
), up 10.4%,
Senesco Technologies
(
SNTI
), up 10.0% and
(
), up 8.5%.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null